Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.56 |
| ▸ | CA2 | P00918 | 5/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324792 | 1.00 | CA1 (0.56) | CA1CA2CA4CA7CA12 | |
| SCHEMBL25707368 | 0.80 | CA1 (0.50) | CA1CA2CA4CA7CA12 | |
| SCHEMBL25706960 | 0.80 | CA1 (0.50) | CA1CA2CA4CA7CA12 | |
| SCHEMBL29174790 | 0.78 | CA1 (0.51) | CA1CA2CA4CA7CA12 | |
| SCHEMBL18699211 | 0.78 | PIM1 (0.61) | CA1CA2CA4CA7CA9 | |
| SCHEMBL30704873 | 0.78 | CASP3 (0.62) | CA1CA2CA4CA7PIM1 | |
| SCHEMBL3005504 | 0.78 | CASP3 (0.62) | CA1CA2CA4CA7PIM1 | |
| SCHEMBL28957025 | 0.77 | CA1 (0.54) | CA1CA2CA4CA7CA12 | |
| SCHEMBL13628078 | 0.77 | CUL4A (0.46) | CA1CA2CA4CA7CA12 | |
| SCHEMBL29698136 | 0.77 | CA1 (0.54) | CA1CA2CA4CA7CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | claimed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | claimed |
| JP-2002531498-A | — | — | 2002-09-24 | — | — | JP | claimed |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2002-02-07 | — | — | US | claimed |
| EP-1135123-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000033834-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | claimed |
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | disclosed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | disclosed |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2002-02-07 | — | — | US | disclosed |
| EP-1135123-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000033834-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | disclosed |
| EP-0432648-B1 | Isatine derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1995-08-02 | — | — | EP | disclosed |
| US-5198461-A | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-30 | — | — | US | disclosed |
| EP-0432648-A2 | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | CA1 2537/4885CA2 821/4885CA4 3674/4885 |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | CA1 2061/4885CA2 450/4885CA4 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.